| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.046 | 0.4 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | AP-24534 | FIMM | pan-cancer | AAC | -0.16 | 0.4 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | -0.047 | 0.4 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |